Moleculin BiotechMBRX +3.95%30 14-Day RSI is 42.49 as of Jul. 09, 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,419 Biotechnology companies, Moleculin Biotech ranks better than 69.27% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Moleculin Biotech 14-Day RSI Related Terms
MBRX vs JAGX, BCDA, AKTX: 14-Day RSI Comparison
For the Biotechnology subindustry, Moleculin Biotech's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moleculin Biotech 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moleculin Biotech's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Moleculin Biotech's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moleculin Biotech (MBRX) has a 14-Day RSI of 42.49 as of Jul. 09, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Moleculin Biotech and its competitors. According to the industry distribution chart, Moleculin Biotech ranks #436 out of 1419 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Moleculin Biotech's 14-Day RSI too high?
Moleculin Biotech's current 14-Day RSI is 42.49. The Biotechnology industry median 14-Day RSI is 48.75. Moleculin Biotech's value of 42.49 is 12.8% below this industry median. Based on the distribution chart, Moleculin Biotech ranks #436 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's 14-Day RSI compare to JAGX and BCDA?
According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #436 out of 1419 companies for 14-Day RSI. This puts Moleculin Biotech in the upper half of its industry. The industry median 14-Day RSI is 48.75. Moleculin Biotech's value of 42.49 is 12.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.75, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moleculin Biotech's current 14-Day RSI of 42.49 is 12.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Moleculin Biotech and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moleculin Biotech's current 14-Day RSI is 42.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current 14-Day RSI of 42.49. The current 14-Day RSI is 42.49 and 12.8% below the Biotechnology industry median of 48.75. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current 14-Day RSI is 42.49 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score
Get the complete analysis for MBRX
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBRX has been successfully added to your 